EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

A comparative study using Xpert MTB/RIF and culture methods evaluates MassARRAY technology for rapid detection of Mycobacterium tuberculosis and drug resistance

Sufang Wu, Lulu Ge, Shulan Zheng, Xiaocui Ma, Ruixia Liang, Baolong Zhang

Frontiers in Cellular and Infection Microbiology · 09.07.2025 · 15

DOI: 10.3389/fcimb.2025.1539240 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 09.07.2025. Verfasst von Sufang Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tuberculosis, Henan Provincial Chest Hospital, Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant, Drug Resistance, Bacterial, Molecular Diagnostic Techniques. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Henan Provincial Science and Technology Research Project, Jianghan University, Natural Science Foundation of Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB) remains a major global health threat, with the urgent need for rapid and accurate diagnostic methods to improve control and treatment outcomes. This study evaluates the performance of MassARRAY technology for detecting Mycobacterium tuberculosis (MTB) and identifying drug resistance, compared to traditional culture methods and Xpert MTB/RIF. From July 2021 to February 2024, bronchoalveolar lavage fluid (BALF) samples from 289 suspected pulmonary tuberculosis patients at Henan Provincial Chest Hospital, China, were tested using MassARRAY, Xpert MTB/RIF, and conventional culturing techniques. The performance of each method was assessed for MTB detection, and the ability of MassARRAY to identify drug resistance was compared with standard drug susceptibility testing (DST). MassARRAY demonstrated a sensitivity of 96.5% and a specificity of 34.6% for MTB detection, outperforming the Xpert MTB/RIF assay in sensitivity (94.7%) but showing lower specificity. In detecting rifampicin resistance, MassARRAY achieved concordance rates of 83.93% with Xpert MTB/RIF and 72.73% with DST. Furthermore, MassARRAY successfully identified key genetic mutations associated with drug resistance, such as rpoB 531 for rifampicin and katG 315 for isoniazid. MassARRAY demonstrated high concordance with DST for several drugs, including isoniazid, kanamycin, and streptomycin, but exhibited limitations in detecting resistance to pyrazinamide, clofazimine, cycloserine, and linezolid. Overall, MassARRAY provides a rapid, cost-effective, and high-throughput diagnostic platform for MTB and drug resistance, particularly for first-line anti-tuberculosis drugs. While limitations in specificity and resistance detection for certain second-line drugs exist, its ability to rapidly provide comprehensive resistance profiles makes it a valuable tool for TB management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantDrug Resistance, BacterialMolecular Diagnostic TechniquesHumansSensitivity and SpecificityMicrobial Sensitivity TestsRifampinBronchoalveolar Lavage FluidTuberculosis, PulmonaryChinaAntitubercular AgentsBacterial ProteinsFemaleMutationMale

Stichwörter der Autor:innen

MassARRAYMycobacterium tuberculosisdrug resistancemolecular diagnosistuberculosis

Substanzen

RifampinAntitubercular AgentsBacterial Proteins

Autor:innen und Institutionen

  • Department of Tuberculosis, Henan Provincial Chest Hospital, Zhengzhou University, Zhengzhou, Henan, China.
  • Tuberculosis Clinical Research Center of Henan Province, Zhengzhou, Henan, China.
  • Children`s Hospital Affiliated to Zhengzhou University, Henan Key Laboratory of Pediatric Genetics and Metabolic Diseases, Zhengzhou, Henan, China.
  • Institute for Systems Biology, School of Life Sciences, Jianghan University, Wuhan, Hubei, China.

Förderung

  • Henan Provincial Science and Technology Research Project
  • Jianghan University
  • Natural Science Foundation of Henan Province

Zitieren

APA

Wu, S., Ge, L., Zheng, S., Ma, X., Liang, R., & Zhang, B. (2025). A comparative study using Xpert MTB/RIF and culture methods evaluates MassARRAY technology for rapid detection of Mycobacterium tuberculosis and drug resistance. Frontiers in Cellular and Infection Microbiology, 15. https://doi.org/10.3389/fcimb.2025.1539240

Vancouver

Wu S, Ge L, Zheng S, Ma X, Liang R, Zhang B. A comparative study using Xpert MTB/RIF and culture methods evaluates MassARRAY technology for rapid detection of Mycobacterium tuberculosis and drug resistance. Frontiers in Cellular and Infection Microbiology. 2025;15. doi:10.3389/fcimb.2025.1539240

BibTeX
@article{Wu2025,
  author = {Wu, Sufang and Ge, Lulu and Zheng, Shulan and Ma, Xiaocui and Liang, Ruixia and Zhang, Baolong},
  title = {A comparative study using Xpert MTB/RIF and culture methods evaluates MassARRAY technology for rapid detection of Mycobacterium tuberculosis and drug resistance},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fcimb.2025.1539240}
}
Kostenlos starten →